Scientech Research LLC Has $910,000 Stake in Exelixis, Inc. $EXEL

by · The Markets Daily

Scientech Research LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,651 shares of the biotechnology company’s stock after purchasing an additional 629 shares during the period. Scientech Research LLC’s holdings in Exelixis were worth $910,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. Hemington Wealth Management grew its position in Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 522 shares in the last quarter. Colonial Trust Co SC increased its holdings in shares of Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 765 shares during the period. Bartlett & CO. Wealth Management LLC acquired a new position in shares of Exelixis in the 1st quarter valued at about $37,000. Costello Asset Management INC acquired a new position in shares of Exelixis in the 1st quarter valued at about $39,000. Finally, Harbour Investments Inc. increased its holdings in shares of Exelixis by 900.0% in the 1st quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 990 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Trading Up 1.3%

Shares of NASDAQ EXEL opened at $37.88 on Monday. The business has a fifty day simple moving average of $40.61 and a 200 day simple moving average of $39.61. The firm has a market capitalization of $10.20 billion, a price-to-earnings ratio of 18.21, a PEG ratio of 0.78 and a beta of 0.32. Exelixis, Inc. has a one year low of $25.12 and a one year high of $49.62.

Exelixis (NASDAQ:EXEL – Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. During the same period in the prior year, the company posted $0.84 earnings per share. Exelixis’s revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

EXEL has been the topic of a number of research reports. HC Wainwright dropped their target price on Exelixis from $53.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Stifel Nicolaus increased their price objective on Exelixis from $38.00 to $41.00 and gave the company a “hold” rating in a research report on Tuesday, July 29th. Royal Bank Of Canada reduced their price objective on Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 29th. Stephens raised Exelixis from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $29.00 to $60.00 in a research report on Tuesday, June 24th. Finally, Barclays increased their price objective on Exelixis from $29.00 to $40.00 and gave the company an “equal weight” rating in a research report on Thursday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.06.

Get Our Latest Analysis on EXEL

About Exelixis

(Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

See Also

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).